Pablo Legorreta - Director, Epizyme, Inc

As of May 19, 2022


Pablo Legorreta Net Worth

  • Net worth is estimated to be at least $19.58M
  • Owns at least 31,833,334 units of Epizyme, Inc stock

Pablo Legorreta Trading

  • Largest purchase of shares was 22,666,667 units , worth over $34M on February 1, 2022
  • In total has made about 5 transactions over 2 years
  • Usually trades in June and February, with the busiest year in 2020 and 2022

Pablo Legorreta, RP Management LLC, RPI Finance Trust, Royalty Pharma Investments ICAV

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Pablo Legorreta Mailing Address

  • Mailing address is 110 E 59th Street Suite 3300 New York NY 10022 NY

Epizyme, Inc Executive Compensation

Name
Year
Salary
Bonus
Restricted Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Robert B. Bazemore Jr. 2020 $650,000 - $3,237,620 $4,103,853 $370,500 $96,369 $8,458,342
Robert B. Bazemore Jr. 2019 $592,937 - $1,105,393 $2,060,531 $409,127 $5,630 $4,173,618
Robert B. Bazemore Jr. 2018 $575,667 - - $2,748,939 $320,575 $5,690 $3,650,871
Paolo Tombesi 2020 $460,000 - $250,006 $750,730 $174,800 $48,198 $1,683,734
Paolo Tombesi 2019 $168,901 - $612,848 $1,173,669 $76,076 $146,971 $2,178,465
Matthew E. Ros 2020 $447,982 - $250,006 $750,730 $174,800 $11,271 $1,634,789
Matthew E. Ros 2019 $432,600 - $538,793 $899,137 $199,861 $11,598 $2,081,989
Matthew E. Ros 2018 $420,000 - - $1,099,576 $187,100 $12,214 $1,718,890
Dr. Shefali Agarwal 2020 $478,000 - $274,990 $825,799 $199,804 $7,154 $1,785,747
Dr. Shefali Agarwal 2019 $463,500 - $894,607 $1,255,325 $265,122 $8,652 $2,887,206
Dr. Shefali Agarwal 2018 $199,615 $125,000 - $1,472,846 $200,500 $1,648 $1,999,609
Jeffery L. Kutok, M.D., Ph.D. 2020 $337,500 $85,000 $374,996 $1,124,996 $134,663 $6,813 $2,063,968
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1571498/000119312521138283/d839557ddef14a.htm

Epizyme, Inc Insider Trading

  • The most recent transaction was 2,741 units sold on April 13, 2022 by Jeffery Kutok worth over $2.47K
  • In the last 9 years, insiders at Epizyme, Inc sold an estimated value of $153.29M and bought an estimated value of $377.73M
  • The most active traders are David Mott, Director,  Robert Copeland, President Research and CSO,  and Andrew Singer, EVP & CFO
  • Insider trading is most common in June, with the busiest year in 2014
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1